Abeona Therapeutics (STU:PCJ) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PCJ Abeona Therapeutics Inc STU:PCJ
51 GF Score
Price €6.23
GF Value €15.12
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Abeona Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:PCJ
51GF Score
Abeona Therapeutics Inc STU:PCJ
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Abeona Therapeutics (STU:PCJ) Overvalued in 2026?

Based on GuruFocus' analysis, Abeona Therapeutics stock appears to be undervalued. The current stock price of €6.23 is trading 58.8% below its estimated GF Value™ of €15.12. GuruFocus considers Abeona Therapeutics to be Possible Value Trap.

Key valuation signals for STU:PCJ:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €15.12 vs. price of €6.23 (58.8% below fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the STU:PCJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Abeona Therapeutics Business Description

Other Exchanges ABEO:USA0H7R:UK
Address 6555 Carnegie Avenue, 4th Floor, Cleveland, OH, USA, 44103
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
51GF Score

Get the complete analysis for STU:PCJ

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.23
Price
€15.12
GF Value